Amgen owes $20.2 mln in antibody patent lawsuit, US jury says
Amgen owes $20.2 mln in antibody patent lawsuit, US jury says By Blake Brittain
June 12 (Reuters) - Amgen AMGN.O subsidiary Teneobio must pay biotech company Harbour Antibodies $20.2 million in damages for infringing a patent related to antibodies used in biologic drugs, a federal jury in Delaware said on Friday.
The jury agreed with Harbour that Teneobio's UniRat platform violated Harbour's patent rights in technology for using genetically engineered mice to produce antibodies.
Harbour's Harbour Mice are used to create antibodies for the research, development and production of biologic drugs.
Biologics are made from biological cells, unlike traditional pharmaceuticals, and are among the most complex and expensive drugs on the market.
Harbour, a Dutch subsidiary of China-based Harbour BioMed, sued Teneobio in 2021, arguing that Teneobio's UniRat system for genetically engineering rats mimicked its technology.
Amgen bought Teneobio for $900 million earlier that year to bolster its biologics business.
Teneobio denied the allegations and argued the patent was invalid.
Spokespeople for the companies did not immediately respond to requests for comment.
(Reporting by Blake Brittain in Washington)
Recent news on Amgen
See all newsUS RESEARCH ROUNDUP-Apple, Kaiser Aluminum, Reliance
Brief: Amgen Says Imdelltra Combo Reduced Risk Of Death By 58% In First-Line Lung Cancer
Corrected: Amgen drug combined with immunotherapy extends survival in lung cancer trial
US RESEARCH ROUNDUP- Amgen, Lockheed Martin, Norfolk Southern
Eli Lilly hits record high as healthcare stocks rally